Cargando…

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). However, most patients eventually develop resistance to these therapies, underscoring the need for effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqi, Tanya, Soumerai, Jacob D., Dorritie, Kathleen A., Stephens, Deborah M., Riedell, Peter A., Arnason, Jon, Kipps, Thomas J., Gillenwater, Heidi H., Gong, Lucy, Yang, Lin, Ogasawara, Ken, Thorpe, Jerill, Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652916/
https://www.ncbi.nlm.nih.gov/pubmed/34699592
http://dx.doi.org/10.1182/blood.2021011895
_version_ 1785136317675339776
author Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Yang, Lin
Ogasawara, Ken
Thorpe, Jerill
Wierda, William G.
author_facet Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Yang, Lin
Ogasawara, Ken
Thorpe, Jerill
Wierda, William G.
author_sort Siddiqi, Tanya
collection PubMed
description Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). However, most patients eventually develop resistance to these therapies, underscoring the need for effective new therapies. We report results of the phase 1 dose-escalation portion of the multicenter, open-label, phase 1/2 TRANSCEND CLL 004 (NCT03331198) study of lisocabtagene maraleucel (liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory CLL/SLL. Patients with standard- or high-risk features treated with ≥3 or ≥2 prior therapies, respectively, including a BTKi, received liso-cel at 1 of 2 dose levels (50 × 10(6) or 100 × 10(6) CAR(+) T cells). Primary objectives included safety and determining recommended dose; antitumor activity by 2018 International Workshop on CLL guidelines was exploratory. Minimal residual disease (MRD) was assessed in blood and marrow. Twenty-three of 25 enrolled patients received liso-cel and were evaluable for safety. Patients had a median of 4 (range, 2-11) prior therapies (100% had ibrutinib; 65% had venetoclax) and 83% had high-risk features including mutated TP53 and del(17p). Seventy-four percent of patients had cytokine release syndrome (9% grade 3) and 39% had neurological events (22% grade 3/4). Of 22 efficacy-evaluable patients, 82% and 45% achieved overall and complete responses, respectively. Of 20 MRD-evaluable patients, 75% and 65% achieved undetectable MRD in blood and marrow, respectively. Safety and efficacy were similar between dose levels. The phase 2 portion of the study is ongoing at 100 × 10(6) CAR(+) T cells. This trial was registered at clinicaltrials.gov as NCT03331198.
format Online
Article
Text
id pubmed-10652916
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-106529162021-10-28 Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL Siddiqi, Tanya Soumerai, Jacob D. Dorritie, Kathleen A. Stephens, Deborah M. Riedell, Peter A. Arnason, Jon Kipps, Thomas J. Gillenwater, Heidi H. Gong, Lucy Yang, Lin Ogasawara, Ken Thorpe, Jerill Wierda, William G. Blood Clinical Trials and Observations Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). However, most patients eventually develop resistance to these therapies, underscoring the need for effective new therapies. We report results of the phase 1 dose-escalation portion of the multicenter, open-label, phase 1/2 TRANSCEND CLL 004 (NCT03331198) study of lisocabtagene maraleucel (liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory CLL/SLL. Patients with standard- or high-risk features treated with ≥3 or ≥2 prior therapies, respectively, including a BTKi, received liso-cel at 1 of 2 dose levels (50 × 10(6) or 100 × 10(6) CAR(+) T cells). Primary objectives included safety and determining recommended dose; antitumor activity by 2018 International Workshop on CLL guidelines was exploratory. Minimal residual disease (MRD) was assessed in blood and marrow. Twenty-three of 25 enrolled patients received liso-cel and were evaluable for safety. Patients had a median of 4 (range, 2-11) prior therapies (100% had ibrutinib; 65% had venetoclax) and 83% had high-risk features including mutated TP53 and del(17p). Seventy-four percent of patients had cytokine release syndrome (9% grade 3) and 39% had neurological events (22% grade 3/4). Of 22 efficacy-evaluable patients, 82% and 45% achieved overall and complete responses, respectively. Of 20 MRD-evaluable patients, 75% and 65% achieved undetectable MRD in blood and marrow, respectively. Safety and efficacy were similar between dose levels. The phase 2 portion of the study is ongoing at 100 × 10(6) CAR(+) T cells. This trial was registered at clinicaltrials.gov as NCT03331198. The American Society of Hematology 2022-03-24 2021-10-28 /pmc/articles/PMC10652916/ /pubmed/34699592 http://dx.doi.org/10.1182/blood.2021011895 Text en Copyright © 2022 American Society of Hematology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Trials and Observations
Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Yang, Lin
Ogasawara, Ken
Thorpe, Jerill
Wierda, William G.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title_full Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title_fullStr Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title_full_unstemmed Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title_short Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
title_sort phase 1 transcend cll 004 study of lisocabtagene maraleucel in patients with relapsed/refractory cll or sll
topic Clinical Trials and Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652916/
https://www.ncbi.nlm.nih.gov/pubmed/34699592
http://dx.doi.org/10.1182/blood.2021011895
work_keys_str_mv AT siddiqitanya phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT soumeraijacobd phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT dorritiekathleena phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT stephensdeborahm phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT riedellpetera phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT arnasonjon phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT kippsthomasj phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT gillenwaterheidih phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT gonglucy phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT yanglin phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT ogasawaraken phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT thorpejerill phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll
AT wierdawilliamg phase1transcendcll004studyoflisocabtagenemaraleucelinpatientswithrelapsedrefractorycllorsll